{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 54 of 74', 'dermatologic adverse events associated with targeted cancer therapies. Support.', 'Care Cancer 23, 2231-44 (2015).', '20.', 'Maio, M. Di, Basch, E., Bryce, J. & Perrone, F. Patient-reported outcomes in the', 'evaluation of toxicity of anticancer treatments. Nat. Rev. Clin. Oncol. 13, 319-325', '(2016).', '21. Basch, E. The missing voice of patients in drug-safety reporting. N. Engl. J. Med. 363,', '1-5 (2010).', '22.', 'Atkinson, T. M. et al. The association between clinician-based common terminology', 'criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a', 'systematic review. Supportive Care in Cancer 24, 3669-3676 (2016).', '23.', 'Chren, M. M., Lasek, R. J., Sahay, a P. & Sands, L. P. Measurement properties of', 'Skindex-16 a brief quality-of-life measure for patients with skin diseases. J. Cutan.', 'Med. Surg. 5, 105-10 (2001).', '24.', 'Joshi, S. S. et al. Effects of epidermal growth factor receptor inhibitor-induced', 'dermatologic toxicities on quality of life. Cancer 116, 3916-3923 (2010).', '25.', 'Nardone, B. et al. The effect of hand-foot skin reaction associated with the', 'multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J. Drugs', 'Dermatol. 11, e61-5 (2012).', '26.', 'Rosen, A. C. et al. Impact of dermatologic adverse events on quality of life in 283', 'cancer patients: A questionnaire study in a dermatology referral clinic. Am. J. Clin.', 'Dermatol. 14, 327-333 (2013).', '27.', 'Jatoi, A. et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-', 'induced skin rashes: Results of a placebo-controlled trial from the North Central', 'Cancer Treatment Group (N03CB). Cancer 113, 847-853 (2008).', '28.', 'Atherton, P. J. et al. Using the skindex-16 and common terminology criteria for', 'adverse events to assess rash symptoms: Results of a pooled-analysis (N0993).', 'Support. Care Cancer 20, 1729-1735 (2012).', '29.', 'Chren, M.-M. The Skindex instruments to measure the effects of skin disease on', 'quality of life. Dermatol. Clin. 30, 231-6, xiii (2012).', '30.', \"Basch, E. et al. Development of the National Cancer Institute's Patient-Reported\", 'Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-', 'CTCAE). JNCI J. Natl. Cancer Inst. 106, dju244-dju244 (2014).', '31.', 'Atkinson, T. M. et al. Reliability of adverse symptom event reporting by clinicians.', 'Qual. Life Res. 21, 1159-1164 (2012).', '32.', 'Hay, J. L. et al. Terminology Criteria for Adverse Events ( PRO-CTCAE). 23, 257-269', '(2014).', '33.', \"Dueck, A. C. et al. Validity and Reliability of the U.S. National Cancer Institute's\", 'Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse', 'Events (PRO-CTCAE). JAMA dermatology 1, 1051-1059 (2015).', '34.', 'National Institute for Health and Clinical Excellence (NICE). Guide to the methods of', 'technology appraisal. 1-78 (2009). doi:10.2165/00019053-200826090-00002', '35.', 'Dolan, P. Modeling valuations for EuroQol health states. Med. Care 35, 1095-108', '(1997).', '36.', 'Department of Health Commercial Medidicines Unit. Electronic Marketing Information', 'Tool (eMIT). Available at: http://cmu.dh.gov.uk/electronic-market-information-tool', 'emit/. (Accessed: 14th November 2016)', '37.', 'Joint Formulary Committee. British National Formulary (BNF) 70. 88-150 (2015).', '38.', 'Department of Health. Reference Costs 2015-16. (2016).', '39.', 'Gray, A. M. Applied Methods of Cost-effectiveness Analysis in Health Care (Handbooks', 'in Health Economic Evaluation Series). (Oxford University Press, 2010).', '40.', \"A'Hern, R. P. Sample size tables for exact single-stage phase II designs. Stat. Med.\", '20, 859-866 (2001).', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 55 of 74', '41.', 'Cocks, K. et al. Evidence-based guidelines for determination of sample size and', 'interpretation of the European organisation for the research and treatment of cancer', 'quality of life questionnaire core 30. J. Clin. Oncol. 29, 89-96 (2011).', '42.', 'Cocks, K. et al. Evidence-based guidelines for interpreting change scores for the', 'European Organisation for the Research and Treatment of Cancer Quality of Life', 'Questionnaire Core 30. Eur. J. Cancer 48, 1713-1721 (2012).', '43.', 'Bottomley, A. et al. Analysing data from patient-reported outcome and quality of life', 'endpoints for cancer clinical trials: a start in setting international standards. The', 'Lancet Oncology 17, e510-e514 (2016).', '44.', 'Grob, J. J., Amonkar, M. M., Karaszewska, B. & Schachter, J. Comparison of', 'dabrafenib and trametinib combination therapy with vemurafenib monotherapy on', 'health-related quality of life in patients with unresectable or', 'Lancet', '16, 1389-', '1398 (2015).', '45.', 'Osoba, D., Rodrigues, G., Myles, J., Zee, B. & Pater, J. Interpreting the significance of', 'changes in health-related quality-of- life scores. J. Clin. Oncol. 16, 139-144 (1998).', '46.', 'Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised', 'RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).', '47.', 'Schag, C. C., Heinrich, R. L. & Ganz, P. A. Karnofsky performance status revisited:', 'Reliability, validity, and guidelines. J. Clin. Oncol. 2, 187-193 (1984).', '48.', 'Oken, M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology', 'Group. American Journal of Clinical Oncology 5, 649-656 (1982).', '49.', 'Buccheri, G., Ferrigno, D. & Tamburini, M. Karnofsky and ECOG performance status', 'scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single', 'institution. Eur. J. Cancer Part A 32, 1135-1141 (1996).', '50.', 'The Criteria Committee of the New York Heart & Association. Nomenclature and', 'Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Human Biology 83,', '(1994).', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}